Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Henry Ford Hospital
mi
from
Detroit, MI
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
St. Louis University Hospital
mi
from
St. Louis, MO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
St. Louis University Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Columbia University
mi
from
New York, NY
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Baylor Health Care System
mi
from
Dallas, TX
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Baylor Health Care System
mi
from
Dallas, TX
Click here to add this to my saved trials
The Effects of Pre-operative Physical Therapy Education
Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial
Status: Enrolling
Updated:  8/16/2012
St. Mary's of Michigan
mi
from
Saginaw, MI
The Effects of Pre-operative Physical Therapy Education
Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial
Status: Enrolling
Updated: 8/16/2012
St. Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
The Effects of Pre-operative Physical Therapy Education
Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial
Status: Enrolling
Updated:  8/16/2012
St. Mary's of Michigan
mi
from
Saginaw, MI
The Effects of Pre-operative Physical Therapy Education
Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial
Status: Enrolling
Updated: 8/16/2012
St. Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study
Status: Enrolling
Updated:  8/17/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244: A Pilot Study
Status: Enrolling
Updated: 8/17/2012
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
E-health Intervention for Cancer Survivors 2.0
E-Health Intervention for Cancer Survivors 2.0
Status: Enrolling
Updated:  8/20/2012
Northwestern University
mi
from
Chicago, IL
E-health Intervention for Cancer Survivors 2.0
E-Health Intervention for Cancer Survivors 2.0
Status: Enrolling
Updated: 8/20/2012
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors
Status: Enrolling
Updated:  8/21/2012
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) for Relapsed/Refractory Pediatric Solid Tumors
Status: Enrolling
Updated: 8/21/2012
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Eastern Regional Medical Center
mi
from
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Eastern Regional Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
University of California, Irvine
mi
from
Irvine, CA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
University of California, Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
UMDNJ
mi
from
Newark, NJ
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
UMDNJ
mi
from
Newark, NJ
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Beth Israel Med Ctr
mi
from
New York, NY
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated:  8/21/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
A Phase II, Open Label, Non-randomized, Multi-center, Pilot, Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug
Status: Enrolling
Updated: 8/21/2012
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Home Telemonitoring for Patients With Lung Cancer
PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca
Status: Enrolling
Updated:  8/21/2012
WVU Mary Babb Randolph Cancer Center and Ruby Hospital
mi
from
Morgantown, WV
Home Telemonitoring for Patients With Lung Cancer
PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca
Status: Enrolling
Updated: 8/21/2012
WVU Mary Babb Randolph Cancer Center and Ruby Hospital
mi
from
Morgantown, WV
Click here to add this to my saved trials
Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated:  8/22/2012
Oncology Research Associates
mi
from
Scottsdale, AZ
Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated: 8/22/2012
Oncology Research Associates
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated:  8/22/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated: 8/22/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated:  8/22/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Phase 1 Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
A Phase 1, Open-label, Dose Escalation Study of ONX 0912 Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors
Status: Enrolling
Updated: 8/22/2012
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers
Status: Enrolling
Updated:  8/23/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
Phase I/II Study of Chemoprevention With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Erlotinib (OSI-774, Tarceva) and Cyclooxygenase-2 (COX-2) Inhibitor (Celecoxib) in Premalignant Lesions of Head and Neck of Former Smokers
Status: Enrolling
Updated: 8/23/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Fayetteville, AR
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Hartford, CT
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Miami, FL
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Athens, GA
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Athens, GA
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Chicago, IL
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Scarborough, ME
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Lansing, MI
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Minneapolis, MN
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Missoula, MT
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Brooklyn, NY
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Cincinnati, OH
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Charleston, SC
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Rapid City, SD
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  8/24/2012
Clinical Research Facility
mi
from
Seattle, WA
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 8/24/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  8/24/2012
University of Kansas Medical Centner
mi
from
Kansas City, KA
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 8/24/2012
University of Kansas Medical Centner
mi
from
Kansas City, KA
Click here to add this to my saved trials
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  8/24/2012
University of Nebraska & Omaha VA
mi
from
Omaha, NE
Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 8/24/2012
University of Nebraska & Omaha VA
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Marin Specialty Care
mi
from
Greenbrae, CA
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Marin Specialty Care
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
St Mary's Medical Center
mi
from
San Francisco, CA
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
St Mary's Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Cancer Center At Blessing Hospital
mi
from
Quincy, IL
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Cancer Center At Blessing Hospital
mi
from
Quincy, IL
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Meritus Center For Clinical Research
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated:  8/24/2012
Arena Oncology Associates PC
mi
from
Lake Success, NY
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy
Status: Enrolling
Updated: 8/24/2012
Arena Oncology Associates PC
mi
from
Lake Success, NY
Click here to add this to my saved trials